Programme

Room 209
2022-09-02
19:00-20:05
AASLD-IDDF- HKASLD Joint Symposium – Hot Topics in Chronic Hepatitis B
19:00
Welcome remarks and introduction
19:05
Debate: Patients who are on antiviral therapy for chronic hepatitis B and have low HCC risk scores can stop HCC screening
19:35
Does peginterferon have a role in HBV cure programs?
19:50
Will new HBV biomarkers help us select agents to cure HBV?
Lecture Theatre 1B
2022-09-03
09:00-10:15
Updates in HBV
09:00
HBV cure with direct-acting antivirals - are we getting close?
09:20
Watch out HBV in the era of COVID-19
09:40
Eliminating mother-to-child transmission of HBV
10:00
Q & A
Lecture Theatre 1B
2022-09-03
10:45-12:00
Best practices in NAFLD/MAFLD
10:45
Existing metabolic drugs for the treatment of NASH
11:05
FXR agonists and FGF analogues
11:25
MRI assessment of treatment response and prognosis
11:45
Q & A
Room 209
2022-09-04
11:00-12:30
Towards control of viral hepatitis
11:00
Eliminating HCV in lockdown
11:25
Disease burden of viral hepatitis in Hong Kong – should we treat more?
11:50
Will immunomodulatory treatment contribute to HBV elimination?
12:15
Q & A
Lecture Theatre 1B
2022-09-04
14:30-16:00
General hepatology updates
14:30
Systemic treatments for HCC
14:55
Updates in autoimmune liver diseases
15:20
What is new in the Baveno VII consensus?
15:45
Q & A
AASLD-IDDF- HKASLD Joint Symposium – Hot Topics in Chronic Hepatitis B
Room 209
2022-09-02
19:00
19:00
Welcome remarks and introduction
19:05
Debate: Patients who are on antiviral therapy for chronic hepatitis B and have low HCC risk scores can stop HCC screening
19:35
Does peginterferon have a role in HBV cure programs?
19:50
Will new HBV biomarkers help us select agents to cure HBV?
Updates in HBV
Lecture Theatre 1B
2022-09-03
09:00
09:00
HBV cure with direct-acting antivirals - are we getting close?
09:20
Watch out HBV in the era of COVID-19
09:40
Eliminating mother-to-child transmission of HBV
10:00
Q & A
Best practices in NAFLD/MAFLD
Lecture Theatre 1B
2022-09-03
10:45
10:45
Existing metabolic drugs for the treatment of NASH
11:05
FXR agonists and FGF analogues
11:25
MRI assessment of treatment response and prognosis
11:45
Q & A
Towards control of viral hepatitis
Room 209
2022-09-04
11:00
11:00
Eliminating HCV in lockdown
11:25
Disease burden of viral hepatitis in Hong Kong – should we treat more?
11:50
Will immunomodulatory treatment contribute to HBV elimination?
12:15
Q & A
General hepatology updates
Lecture Theatre 1B
2022-09-04
14:30
14:30
Systemic treatments for HCC
14:55
Updates in autoimmune liver diseases
15:20
What is new in the Baveno VII consensus?
15:45
Q & A